A First-in-Human, Open-Label, Dose Escalation and Expansion Study of JR8603 in Patients with Advanced Solid Tumors
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs JR 8603 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors JiaRay Therapeutics
- 29 Jan 2025 New trial record